Journal Article

Integrating D4Z4 methylation analysis into clinical practice: improvement of FSHD molecular diagnosis through distinct thresholds for 4qA/4qA and 4qA/4qB patients

Tufano, Laura, Petillo, Roberta, Giardina, Emiliano, Risi, Barbara, Petrucci, Antonio, Torri, Francesca, Filosto, Massimiliano, Torchia, Eleonora, Pennisi, Elena Maria, Carraro, Elena, Mongini, Tiziana Enrica, Garibaldi, Matteo, Siciliano, Gabriele, Cascella, Raffaella, Manfroi, Elisabetta, Caltagirone, Carlo, Caria, Filomena, Scutifero, Marianna, Massa, Roberto, Bortolani, Sara, Rodolico, Carmelo, Casali, Carlo, Politano, Luisa, Mandich, Paola, Frongia, Annalia, Vercelli, Liliana, Proietti Piorgo, Emma, Sancricca, Cristina, Gioiosa, Valeria, Gragnani, Francesca, Tasca, Giorgio, Grandis, Marina, Previtali, Stefano Carlo, Maioli, Maria Antonietta, Pugliese, Alessia, Ricci, Enzo, Frezza, Erica, Pane, Marika, Sansone, Valeria, Primiano, Guido, Megalizzi, Domenica, Strafella, Claudia, Ricci, Giulia, Ravera, Beatrice, Trastulli, Giulia, Colantoni, Luca, Monforte, Mauro, Gadaleta, Giulio, Zampatti, Stefania, Gerardi, Francesca, Passamano, Luigia

2024

Overview

Background Facioscapulohumeral dystrophy (FSHD) is a myopathy characterized by the loss of repressive epigenetic features affecting the D4Z4 locus (4q35). The assessment of DNA methylation at two regions ( DUX4 -PAS and DR1) of D4Z4 locus proved to be an effective method to detect epigenetic signatures compatible with FSHD. The present study aims at validating the employment of this method into clinical practice and improving the protocol by refining the classification thresholds of 4qA/4qA patients. To this purpose, 218 subjects with clinical suspicion of FSHD collected in 2022–2023 were analyzed. Each participant underwent in parallel the traditional FSHD molecular testing ( D4Z4 sizing) and the proposed methylation assay. The results provided by both analyses were compared to evaluate the concordance and calculate the performance metrics of the methylation test. Results Among the 218 subjects, the 4q variant type distribution was 54% 4qA/4qA, 43% 4qA/4qB and 3% 4qB/4qB. The methylation analysis was performed only on carriers of at least one 4qA allele. After refining the classification threshold, the test reached the following performance metrics: sensitivity = 0.90, specificity = 1.00 and accuracy = 0.93. These results confirmed the effectiveness of the methylation assay in identifying patients with genetic signature compatible with FSHD1 and FSHD2 based on their DUX4 -PAS and DR1 profile, respectively. The methylation data were also evaluated with respect to the clinical information. Conclusions The study confirmed the ability of the method to accurately identify methylation profiles compatible with FSHD genetic signatures considering the 4q genotype. Moreover, the test allows the detection of hypomethylated profiles in asymptomatic patients, suggesting its potential application in identifying preclinical conditions in patients with positive family history and FSHD genetic signatures. Furthermore, the present work emphasizes the importance of interpreting methylation profiles considering the patients’ clinical data.

• Publisher: BioMed Central,BioMed Central Ltd,BMC
• Subject: Adult / Aged / Biomedical and Life Sciences / Biomedicine / Chromosomes, Human, Pair 4 - genetics / DNA methylation / DNA Methylation - genetics / Epigenesis, Genetic - genetics / Epigenetic biomarker / Epigenetic inheritance / Female / FSHD / FSHD diagnosis / FSHD signature / Gene Function / Homeodomain Proteins - genetics / Human Genetics / Humans / Male / Methylation / Middle Aged / Muscular Dystrophy, Facioscapulohumeral - diagnosis / Muscular Dystrophy, Facioscapulohumeral - genetics / Neuromuscular diseases / Young Adult